Form 4: MBX Biosciences CEO Receives Stock Grant
Insider Transaction (Form 4)
Steven L. Hoerter, President and CEO and a Director of MBX Biosciences, Inc., reported multiple transactions in common stock on August 3, 2026.
Summary
- Grant/award: acquired 71,000 Common Stock on August 3, 2026; holds 82,938 after (Direct).
- Grant/award: acquired 331,000 Stock option (right to buy) on August 3, 2026; holds 331,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Steven L. Hoerter — Director, Officer (President and CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-03 | Grant/award | Common Stock | 71,000 | — | — | 82,938 |
| 2026-08-03 | Grant/award | Stock option (right to buy) | 331,000 | — | — | 331,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-03 | Grant/award (71,000 shares) |
| 2026-08-03 | Grant/award (331,000 shares) |
Keywords
insider transaction, Form 4, MBX, MBX Biosciences, Inc., neutral, Steven L. Hoerter
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.